Medify Solutions Limited
(OTC: MFYS)
View the StockGuru Profile for
Medify Solutions Limited:
http://www.stockguru.com/profiles/mfys/
Medify Solutions Limited
Medify Solutions Limited (OTC: MFYS) is a group of companies that are focused on the development, taking to market and delivery of leading edge mobile solutions for the healthcare market. With operations across the EU, Medify are at the forefront of the technology revolution in patient care.
Medify Solutions is the first business to have developed a Secure Remote Access product for the Healthcare market, addressing critical requirements of Governmental strategic directives, using the latest integrated mobile client based technologies. Medify provides connectivity application solutions with partners such as CM Isitel spa, Oracle, EMIS and BT. Group headquarters are in the UK, with a management presence in Italy, Spain, Switzerland and the US.
Products & Solutions
Remote Access to patient notes is the ideal solution for healthcare professionals in their quest to provide better, more efficient, and more informed quality care to the patients. This application has not been available until Medify Solutions development of the client application whereby healthcare professionals have the ability to securely access, update, and review patient records, from anywhere in real time via a normal GSM/GPRS/UMTS connection. MedifyRemote will integrate into any patient record system with no capital expenditure required on new hardware, and with immediate user access ‘out of the box’.
Utilising Microsoft Pocket PC, the application allows remote access to Patient notes and clinical systems in real time. Medify’s technology allows secure real time access; there is no downloading, nor time delay, to the patient notes accessed and updated in the field. Traditionally field-based healthcare professionals have been forced to either download all clinical information to a laptop or PDA, storing permanently all private and confidential patient information; this being a high-risk approach. The alternative has been to carry around the actual paper-based patient notes; with a similar inherent risk. Many Departments’ of Health have dictated that all patient records must be held electronically and remote access to these has to be delivered within the defined plan.
MedifyRemote has many benefits not only in terms of continuity of care, patient and note hand over, single data entry, security and clinical governance, and the need of the doctor and nurse. Currently, MedifyRemote is the only application to provide real time remote secure access to patient notes and the only approved solution for the EMIS system in the UK. Medify has an exclusive contract with EMIS to provide its technology to EMIS users. Currently EMIS supplies its service to 60% of the NHS UK primary care market (circa 150,000 healthcare professionals).
MedifyRemote can be billed monthly per user or as a one-time fee. In many cases the Pocket PC is issued at no cost within a contract (air-time use can be billed directly to the user or as a package from Medify). This product and service represents a compliant, complete and highly cost and time efficient mobile solution to key priority areas currently identified in the Governmental and strategic directives.
Product Roll Out
On September 1st, 2006, Medify Solutions will roll out its ‘remote access to patient notes’ product, MedifyRemote, to its National Health Service (NHS) customers. The first NHS site will be in Doncaster in the north of England. The roll out is for approximately 2500 users.
This site is leading the way for the rest of the UK in terms of development and user testing of the powerful Medify Remote live product, which will bring many benefits for patients and users in terms of greater efficiency and more accurate transfer of information.
Operating through its N3 approved secure connection to the NHS patient database; Medify will begin the roll out to its live NHS customers. This will be coordinated through corporate partners who are providing the patient record software and airtime connection to the NHS.
Medify has the approved connection to NHS’ N3, the secure national IT network and has contracts to provide the service to NHS Healthcare professionals, which will now roll out over the next 12 months. As the only provider to offer the service Medify is set to achieve significant revenues starting on the 1st of September 2006.
Magazine Feature
Medify Solutions was featured in the Summer 2006 edition of The NAPC Review, an official publication of the National Association of Primary Care (NAPC).
The NAPC is a non-political, non profit-making membership organisation that represents and supports the interests of all primary health care professionals and organisations. The NAPC represents and negotiates Primary Care Groups’ interests with central Government and other political parties. In addition to working with the NHS Executive, the Secretary of State and the Chief Medical Officer, members’ interests are represented on many national working groups, which provide opportunities for creating and shaping policies.
View the StockGuru Profile for
Medify Solutions Limited:
http://www.stockguru.com/profiles/mfys/
We Invite you to Visit the All New StockGuru Blog!
Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.
Click HERE to visit the Blog, or go to:
http://stockguru.com/blog/
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4268. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $15,000 by a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.